Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionstructural molecule activity

MYBPH OBSCN MRPL19 LMNTD2 SHANK3 ANK1

5.23e-04891246GO:0005198
GeneOntologyMolecularFunctionstructural constituent of muscle

MYBPH OBSCN

1.21e-0343242GO:0008307
GeneOntologyCellularComponentM band

MYBPH OBSCN ANK1

5.85e-0631243GO:0031430
GeneOntologyCellularComponentA band

MYBPH OBSCN ANK1

2.83e-0552243GO:0031672
GeneOntologyCellularComponentmyosin filament

MYBPH OBSCN

3.73e-0425242GO:0032982
PathwayREACTOME_REGULATION_OF_RUNX1_EXPRESSION_AND_ACTIVITY

AGO4 RUNX1

1.42e-0417152M27788
Pubmed

Localization of ank1.5 in the sarcoplasmic reticulum precedes that of SERCA and RyR: relationship with the organization of obscurin in developing sarcomeres.

OBSCN ANK1

4.56e-07224219002483
Pubmed

Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?

MTHFR XRCC1

4.56e-07224217009149
Pubmed

Obscurin is a ligand for small ankyrin 1 in skeletal muscle.

OBSCN ANK1

4.56e-07224212631729
Pubmed

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

MTHFR XRCC1

4.56e-07224216785472
Pubmed

Mapping the binding site on small ankyrin 1 for obscurin.

OBSCN ANK1

4.56e-07224217720975
Pubmed

MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.

MTHFR XRCC1

1.37e-06324229205204
Pubmed

MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia.

MTHFR XRCC1

1.37e-06324232192442
Pubmed

Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.

MTHFR XRCC1

1.37e-06324223774147
Pubmed

Binding of an ankyrin-1 isoform to obscurin suggests a molecular link between the sarcoplasmic reticulum and myofibrils in striated muscles.

OBSCN ANK1

1.37e-06324212527750
Pubmed

XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.

MTHFR XRCC1

2.74e-06424218851872
Pubmed

Obscurin and KCTD6 regulate cullin-dependent small ankyrin-1 (sAnk1.5) protein turnover.

OBSCN ANK1

2.74e-06424222573887
Pubmed

Molecular interactions with obscurin are involved in the localization of muscle-specific small ankyrin1 isoforms to subcompartments of the sarcoplasmic reticulum.

OBSCN ANK1

2.74e-06424216962094
Pubmed

Influence of DNA repair gene polymorphisms of hOGG1, XRCC1, XRCC3, ERCC2 and the folate metabolism gene MTHFR on chromosomal aberration frequencies.

MTHFR XRCC1

4.56e-06524216997330
Pubmed

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

MTHFR XRCC1

4.56e-06524219672255
Pubmed

Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population.

MTHFR XRCC1

4.56e-06524219492240
Pubmed

ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.

MTHFR XRCC1

4.56e-06524218267032
Pubmed

Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

MTHFR XRCC1

6.83e-06624226314858
Pubmed

Genetic susceptibility of newborn daughters to oxidative stress.

MTHFR XRCC1

6.83e-06624217614221
Pubmed

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

MTHFR XRCC1

6.83e-06624217549067
Pubmed

Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.

MTHFR XRCC1

6.83e-06624220504250
Pubmed

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.

MTHFR XRCC1

9.56e-06724217476281
Pubmed

Genetic polymorphisms in the Hmong population: implications for cancer etiology and survival.

MTHFR XRCC1

9.56e-06724214716779
Pubmed

Single nucleotide polymorphisms in breast cancer.

MTHFR XRCC1

9.56e-06724215010895
Pubmed

XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.

MTHFR XRCC1

9.56e-06724216875718
Pubmed

Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours.

MTHFR XRCC1

1.27e-05824216343742
Pubmed

Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.

MTHFR XRCC1

1.27e-05824221057378
Pubmed

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.

MTHFR XRCC1

1.27e-05824220734048
Pubmed

Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions.

MTHFR XRCC1

1.27e-05824216956909
Pubmed

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.

MTHFR XRCC1

1.27e-05824221048041
Pubmed

Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

MTHFR XRCC1

1.64e-05924216622263
Pubmed

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.

MTHFR XRCC1

1.64e-05924219858398
Pubmed

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.

MTHFR XRCC1

2.05e-051024220216541
Pubmed

Genetic modifiers of carcinogen DNA adducts in target lung and peripheral blood mononuclear cells.

MTHFR XRCC1

2.05e-051024220935060
Pubmed

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

MTHFR XRCC1

2.50e-051124219332728
Pubmed

Oxidative damage to biological macromolecules in Prague bus drivers and garagemen: impact of air pollution and genetic polymorphisms.

MTHFR XRCC1

2.50e-051124220723587
Pubmed

Polymorphisms in DNA repair and metabolic genes in bladder cancer.

MTHFR XRCC1

2.50e-051124214688016
Pubmed

Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism.

MTHFR XRCC1

2.50e-051124215914210
Pubmed

BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin.

MTHFR XRCC1

2.50e-051124220331623
Pubmed

Leukaemia disease genes: large-scale cloning and pathway predictions.

CORO1A RUNX1

2.50e-051124210610183
Pubmed

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

MTHFR XRCC1

3.00e-051224216407418
Pubmed

Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.

MTHFR XRCC1

4.13e-051424219636001
Pubmed

Chromosomal aberrations in railroad transit workers: effect of genetic polymorphisms.

MTHFR XRCC1

4.13e-051424219177501
Pubmed

Single-cell architecture and functional requirement of alternative splicing during hematopoietic stem cell formation.

CORO1A RUNX1

4.13e-051424234995116
Pubmed

Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population (review).

MTHFR XRCC1

4.77e-051524212883749
Pubmed

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

MTHFR XRCC1

4.77e-051524219074750
Pubmed

Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.

MTHFR XRCC1

5.44e-051624220368715
Pubmed

Candidate gene association study of esophageal squamous cell carcinoma in a high-risk region in Iran.

MTHFR XRCC1

5.44e-051624219826048
Pubmed

Allele Frequencies of 25 Polymorphisms Pertaining to Cancer Risk for Japanese, Koreans and Chinese.

MTHFR XRCC1

7.75e-051924212718576
Pubmed

Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.

MTHFR ADAM17 XRCC1

1.24e-0414124318636124
Pubmed

Fgf and Esrrb integrate epigenetic and transcriptional networks that regulate self-renewal of trophoblast stem cells.

PHF3 XRCC1 RUNX1

2.42e-0417724326206133
Pubmed

Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.

MTHFR XRCC1

2.83e-043624218830263
Pubmed

Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients.

MTHFR XRCC1

2.83e-043624212164325
CytobandEnsembl 112 genes in cytogenetic band chr19q13

PPP1R37 WDR88 ASPDH XRCC1

3.17e-031192244chr19q13
CytobandEnsembl 112 genes in cytogenetic band chr1p34

IPP AGO4

1.03e-02294242chr1p34
GeneFamilyFibronectin type III domain containing

MYBPH OBSCN

6.60e-03160142555
GeneFamilyBlood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing

MYBPH OBSCN

6.68e-03161142593
GeneFamilyAnkyrin repeat domain containing

SHANK3 ANK1

1.46e-02242142403
GeneFamilyWD repeat domain containing

WDR88 CORO1A

1.70e-02262142362
DrugKynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; PC3; HT_HG-U133A

MTHFR CORO1A ADAM17 AGO4 RUNX1

1.76e-061982454681_DN
DrugMethoxy-6-harmalan [3589-73-9]; Up 200; 18.6uM; MCF7; HT_HG-U133A

IPP MTHFR PHF3 RUNX1

4.29e-051892445455_UP
DrugCarbarsone [121-59-5]; Up 200; 15.4uM; MCF7; HT_HG-U133A

PPP1R37 MTHFR RUNX1 ANK1

4.75e-051942444110_UP
Drugtris(p-aminophenyl)carbonium pamoate

CORO1A ADAM17

4.77e-0510242CID000024040
DrugNalidixic acid sodium salt hydrate; Down 200; 14.6uM; HL60; HT_HG-U133A

MTHFR PHF3 ADAM17 RUNX1

4.85e-051952442336_DN
DrugEthotoin [86-35-1]; Up 200; 19.6uM; MCF7; HT_HG-U133A

MYBPH MTHFR PHF3 RUNX1

4.85e-051952446052_UP
DrugButamben [94-25-7]; Down 200; 20.6uM; HL60; HT_HG-U133A

MYBPH MTHFR PHF3 RUNX1

4.95e-051962442531_DN
DrugDroperidol [548-73-2]; Down 200; 10.6uM; PC3; HT_HG-U133A

MTHFR PHF3 ADAM17 AGO4

4.95e-051962444629_DN
DrugCefepime hydrochloride [123171-59-5]; Up 200; 7.4uM; MCF7; HT_HG-U133A

MTHFR PHF3 ADAM17 RUNX1

5.04e-051972446237_UP
DrugAustricine [10180-88-8]; Up 200; 14.2uM; MCF7; HT_HG-U133A

MTHFR AGO4 RUNX1 ANK1

5.04e-051972442812_UP
DrugPrimidone [125-33-7]; Down 200; 18.4uM; HL60; HT_HG-U133A

MYBPH MTHFR PHF3 RUNX1

5.04e-051972443065_DN
DrugMefexamide hydrochloride [3413-64-7]; Up 200; 12.6uM; MCF7; HT_HG-U133A

PPP1R37 MTHFR RUNX1 ANK1

5.14e-051982442284_UP
DrugN5,N10-methylene tetrahydrofolic acid

MYBPH MTHFR RUNX1

6.61e-0575243CID000000884
DiseaseL2 Acute Lymphoblastic Leukemia

MTHFR XRCC1 RUNX1

6.89e-0650223C0023453
DiseaseChildhood Acute Lymphoblastic Leukemia

MTHFR XRCC1 RUNX1

7.76e-0652223C0023452
DiseasePrecursor Cell Lymphoblastic Leukemia Lymphoma

MTHFR XRCC1 RUNX1

1.26e-0561223C1961102
Diseaseanemia (is_implicated_in)

MTHFR ANK1

4.80e-0514222DOID:2355 (is_implicated_in)
DiseaseSchizophrenia

MTHFR SHANK3

8.06e-0518222cv:C0036341
Diseaseinflammatory bowel disease (is_implicated_in)

MTHFR ADAM17

9.00e-0519222DOID:0050589 (is_implicated_in)
Diseasechronic myeloid leukemia (is_implicated_in)

MTHFR XRCC1

1.10e-0421222DOID:8552 (is_implicated_in)
Diseasetransitional cell carcinoma (is_implicated_in)

MTHFR XRCC1

1.21e-0422222DOID:2671 (is_implicated_in)
DiseaseThrombocytopenia

MTHFR RUNX1

2.13e-0429222C0040034
Diseasecervical cancer (is_implicated_in)

MTHFR XRCC1

2.28e-0430222DOID:4362 (is_implicated_in)
Diseasehepatitis B (is_implicated_in)

MTHFR XRCC1

3.48e-0437222DOID:2043 (is_implicated_in)
Diseaseliver cirrhosis (is_implicated_in)

MTHFR XRCC1

4.70e-0443222DOID:5082 (is_implicated_in)
Diseaseesophagus squamous cell carcinoma (is_implicated_in)

XRCC1 RUNX1

5.15e-0445222DOID:3748 (is_implicated_in)
Diseaseacute lymphoblastic leukemia (is_implicated_in)

MTHFR XRCC1

7.69e-0455222DOID:9952 (is_implicated_in)
DiseaseMalignant neoplasm of breast

OBSCN WDR88 MRPL19 MTHFR ANK1

9.94e-041074225C0006142
Diseaserenal cell carcinoma (is_implicated_in)

MTHFR XRCC1

1.21e-0369222DOID:4450 (is_implicated_in)
Diseaseurinary bladder cancer (is_implicated_in)

MTHFR XRCC1

1.46e-0376222DOID:11054 (is_implicated_in)

Protein segments in the cluster

PeptideGeneStartEntry
IVTVEPRRRKFHRPI

ANK1

1131

P16157
VAEKDRPHEGTRPVR

CORO1A

211

P31146
HYDVDIKPEKRPRRV

AGO4

46

Q9HCK5
RKHVVEVLDPIRFPL

IPP

216

Q9Y573
LSAHPKRREEDVRPI

MTHFR

351

P42898
RRPDLVVEVAHPKII

ASPDH

66

A6ND91
PKGEVLSEHRIPRRE

LMNTD2

456

Q8IXW0
REHIEVEEKRASPPV

KIZ

306

Q2M2Z5
HKVFVVTRVESPPER

PPP1R37

566

O75864
RPCRREPLVVKEHED

OBSCN

1721

Q5VST9
VLPGQHPRKIEIERR

DNAH1

181

Q9P2D7
VEIKARPPREEHLEL

HEPHL1

796

Q6MZM0
IKITVDGPREPRRHR

RUNX1

166

Q01196
VFKVEGRDIPIVHRV

SEC11C

96

Q9BY50
RENIEAPKIRVPRHL

MYBPH

166

Q13203
KLREVERRLHSPPEV

SYCE1L

171

A8MT33
DREPPEELVHRVKRR

ADAM17

201

P78536
FPIRIKAVHVVNEPR

TTPAL

216

Q9BTX7
VIVDKHRPVEPERRF

MRPL19

61

P49406
VVRDFEHRPKAPVVE

WDR88

136

Q6ZMY6
IPHEPKEVRFVVRSV

SHANK3

1616

Q9BYB0
QVKDIRRPERRHSDP

PHF3

1886

Q92576
VLREHPDYPKIREEI

TTC21A

1296

Q8NDW8
ELRRVAEQKEHRLPP

XRCC1

491

P18887